BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8618269)

  • 1. Clinical and pathological features of hereditary prostate cancer.
    Keetch DW; Humphrey PA; Smith DS; Stahl D; Catalona WJ
    J Urol; 1996 Jun; 155(6):1841-3. PubMed ID: 8618269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of patients with familial versus sporadic prostate cancer.
    Roehl KA; Loeb S; Antenor JA; Corbin N; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 1):2438-42; discussion 2442. PubMed ID: 17085123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
    Djavan B; Mazal P; Zlotta A; Wammack R; Ravery V; Remzi M; Susani M; Borkowski A; Hruby S; Boccon-Gibod L; Schulman CC; Marberger M
    Prostate; 2001 May; 47(2):111-7. PubMed ID: 11340633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
    Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
    J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
    BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
    Siddiqui SA; Sengupta S; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2006 Sep; 176(3):1118-21. PubMed ID: 16890705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.